anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This review focuses on the dual role of platelets in atherosclerosis and thrombosis, exploring their involvement in inflammation, angiogenesis, and plaque formation, as well as their hemostatic and prothrombotic functions. Beyond their thrombotic functions, platelets engage in complex interactions with diverse cell types, influencing disease resolution and progression. The contribution of platelet degranulation helps in the formation of atheromatous plaque, whereas the reciprocal interaction with monocytes adds complexity. Alterations in platelet membrane receptors and signaling cascades contribute to advanced atherosclerosis, culminating in atherothrombotic events. Understanding these multifaceted roles of platelets will lead to the development of targeted antiplatelet strategies for effective cardiovascular disease prevention and treatment. Understanding platelet functions in atherosclerosis and atherothrombosis at different stages of disease will be critical for designing targeted treatments and medications to prevent or cure the disease Through this understanding, platelets can be targeted at specific times in the atherosclerosis process, possibly preventing the development of atherothrombosis.
The invention describes a method for increasing the content of non-psychotropic phytocannabinoid cannabidiol acid (CBDA) and its derivative cannabidiol (CBD) in the inflorescences of fibrous hemp (Cannabis sativa) by applying seed treatment under vacuum before sowing. The seeds are placed in a single layer in a sterile 10 cm diameter Petri dish placed in an airtight 0.05 m3 stainless steel chamber. A vacuum of 100-200 Pa is created in the chamber, the working gas is the residual air. The seeds in the chamber are vacuum treated for 3-7 minutes. The treated seeds are stored at 20-25 ° C in the dark for 4 days, then sown and the plants are grown under normal conditions. Using the described technology - short-term vacuum treatment of fibrous hemp seeds - it is possible to significantly increase the amount of non-psychotropic cannabinoids in the inflorescences of female plants up to 20-25%.0
The patient will undergo OTE using the standard Ivor-Lewis approach. This is a two-stage operation involving a first stage through laparotomy, proximal gastrectomy, D2 nodal dissection, and insertion of feeding jejunostomy. The second stage of the operation will involve a right thoracotomy, thoracic nodal dissection, esophagectomy, and a stapled anastomosis between the residual esophagus and the gastric conduit at the level of the azygous vein.
Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
Ambroxol is a mucolytic agent used for eradicate this class of mucus in patients with cystic fibrosis. However, there are no reports about its bactericide capacity. The purpose of this study is to determine the bactericide, fungicide and anti-biofilm activities of ambroxol against oral microorganisms. The bactericide activity was determined by using the MTT cellular viability assay. The minimum inhibitory concentration was determined for interfering with the growth of oral bacteria. The anti-biofilm capacity of ambroxol was simultaneously analyzed by fluorescence microscopy. Within the obtained results, ambroxol had shown an important bactericide activity from 0.5 mg/ml as a final concentration. The MIC estimated for ambroxol is 1mg/ml against oral bacteria. At this concentration, ambroxol was able to inhibit the formation of oral biofilm. Additionally, it was effective for removing mature biofilm. As a conclusion, ambroxol is an excellent therapeutic option against infectious disease s of bacteria forming biofilm.
Highly myopic patients with vitreoretinal disease requiring pars plana vitrectomy. The 30mm (shaft length) vitrectomy probe (25 gauge) would be used in the surgery.
The present invention discloses a new class of highly fluorescent indicator dyes that are specific for calcium ions. The new fluorescent indicator dyes combine a stilbene-type fluorophore with a tetracarboxylate parent Ca 2+  chelating compound having the octacoordinate pattern of liganding groups characteristic of EGTA and BAPTA. Preferred forms contain extra heterocyclic bridges to reinforce the ethylenic bond of the stilbene and to reduce hydrophobicity. Compared to their widely used predecessor, "quin2", the new dyes offer up to thirty-fold brighter fluorescence, major changes in wavelength (not just intensity) upon Ca 2+  binding, slightly lower affinities for Ca 2+ , slightly longer wavelengths of excitation, and considerably improved selectivity for Ca 2+  over other divalent cations. These properties, particularly the wavelength sensitivity to Ca 2+ , make the dyes useful indicators for many intracellular applications, especially in single cells, adherent cell layers, or bulk tissues. 
     The present invention also discloses an improved method for synthesizing alpha-acyloxyalkyl bromides wherein the bromides so synthesized are free of contaminating bis(1-bromoalkyl)ether. The improved method is exemplified herein in the synthesis of acetoxymethyl bromide, a compound useful in preparing the acetoxymethyl esters disclosed herein as novel Ca 2+  specific fluorescent indicators.
Efficacy studies of Neulasta could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. Approval of this indication was based on efficacy studies conducted in animals and data supporting Neulasta's effect on severe neutropenia in patients with cancer receiving myelosuppressive chemotherapy [see Dosage and Administration (2.1)].

The recommended dose of Neulasta is two doses, 6 mg each, administered one week apart for humans exposed to myelosuppressive doses of radiation. For pediatric patients weighing less than 45 kg, dosing of Neulasta is weight based and is provided in Table 1 [see Dosage and Administration (2.3)]. This dosing regimen is based on population modeling and simulation analyses. The exposure associated with this dosing regimen is expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation [see Clinical Pharmacology (12.3)]. The safety of Neulasta at a dose of 6 mg has been assessed on the basis of clinical experience in patients with cancer receiving myelosuppressive chemotherapy.

The efficacy of Neulasta for the acute radiation syndrome setting was studied in a randomized, placebo-controlled non-human primate model of radiation injury. Rhesus macaques were randomized to either a control (n = 23) or treated (n = 23) cohort. On study day 0, animals (n = 6 to 8 per irradiation day) were exposed to total body irradiation (TBI) of 7.50 ± 0.15 Gy delivered at 0.8 ± 0.03 Gy/min, representing a dose that would be lethal in 50% of animals by 60 days of follow-up (LD50/60). Animals were administered subcutaneous injections of a blinded treatment (control article [5% dextrose in water] or pegfilgrastim [300-319 mcg/kg/day]) on study day 1 and on study day 8. The primary endpoint was survival. Animals received medical management consisting of intravenous fluids, antibiotics, blood transfusions, and other support as required.

Pegfilgrastim significantly (at 0.0014 level of significance) increased 60-day survival in irradiated non-human primates: 91% survival (21/23) in the pegfilgrastim group compared to 48% survival (11/23) in the control group.
Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
BACKGROUND: Eagle jugular syndrome (EJS), recently identified as a cause of cerebrovascular disease (CVD) due to venous obstruction by an elongated styloid process (SP), is reported here alongside a case of concurrent de novo cerebral cavernous malformation (CCM). This study aims to explore the potential causal relationship between EJS and de novo CCM through a comprehensive literature review.
METHOD: Systematic literature reviews, spanning from 1995 to 2023, focused on EJS cases with definitive signs and symptoms and de novo CCM cases with detailed clinical characteristics. Data on the pathophysiology and clinical manifestations of EJS, as well as potential risk factors preceding de novo CCM, were collected to assess the relationship between the two conditions.
RESULT: Among 14 patients from 11 articles on EJS, the most common presentation was increased intracranial hypertension (IIH), observed in 10 patients (71.4%), followed by dural sinus thrombosis in four patients (28.6%). In contrast, 30 patients from 28 articles were identified with de novo CCM, involving 37 lesions. In these cases, 13 patients developed CCM subsequent to developmental venous anomalies (43%), seven following dural arteriovenous fistula (dAVF) (23%), and two after sinus thrombosis (6%). In a specific case of de novo brainstem CCM, the development of an enlarged condylar emissary vein, indicative of venous congestion due to IJV compression by the elongated SP, was noted before the emergence of CCM.
CONCLUSION: This study underscores that venous congestion, a primary result of symptomatic EJS, might lead to the development of de novo CCM. Thus, EJS could potentially be an indicator of CCM development. Further epidemiological and pathophysiological investigations focusing on venous circulation are necessary to clarify the causal relationship between EJS and CCM.
Although the evidence base for genetic susceptibility markers for complex disorders (e.g., diabetes, hypertension, and obesity) and the clinical utility of the related genetic tests has not been demonstrated, all signs suggest that genetics will become increasingly relevant to and integrated into family medicine. In recognition of these emerging genomic innovations and their potential for improving primary care practice, the American Academy of Family Physicians (AAFP), in collaboration with the National Human Genome Research Institute (NHGRI), has made genomic medicine the topic of their 2005 Annual Clinical Focus curriculum. The AAFP is one of the largest medical organizations with a membership that comprises a group of 56,400 active family physicians who deliver care in a broad array of practice settings in rural and urban communities around the United States, Puerto Rico, the Virgin Islands and Guam. This study seeks to take advantage of the plans for AAFP's clinical focus on genomics to characterize family physicians' attitudes and practices related to the genetics of complex disorders. This information could be useful in understanding and shaping the dissemination of genetic medicine in ways that improve the standard of primary care practice. To this end, we propose to conduct two phases of research activity. In the first phase, a web-based survey will be conducted of members of AAFP. In the second phase, a sub-sample of those who complete the survey will be re-contacted; half will be members who have enrolled in a year-long web-based curriculum related to medical genetics, and the other half will be those who have chosen not to enroll in the curriculum.
NEW MATERIAL:Cordycepin derivatives of formula I (R is alkyl). EXAMPLE:2', 5'-O-diacetylcordycepin. USE:An agent for competing with nucleic acid metabolism: it has activity inhibiting RNA synthesis and shows remarkable carcinostatic action on ascitic sarcoma 180 and cancer (ICR mouse). Further it is not deactivated by adenosine deaminease in living bodies. PREPARATION:An acid anhydride of formula III acts on cordycepin of formula II in a solvent such as pyridine to give a compound of formula I. Or an acid halide of formula IV(X is halogen) acts on cordycepin of formula X in a solvent such as pyridine to form a compound of formula V (R' is H, group of formula IV remaining after X is removed), which is hydrolyzed to give a compound of formula I.
The invention provides a polypeptide that is antigenic in a host. The invention also provides a vaccine for use in reducing or preventing  Campylobacter  colonization in a host. The vaccine comprises a polypeptide of the present invention and / or antibodies against the polypeptide of the present invention. The host may be a human, cow, sheep, goat, and chicken. The invention has particular application for reducing or preventing  Campylobacter jejuni  colonization in poultry. The invention also provides a vaccine for use in reducing or preventing campylobacteriosis; and a vaccine composition comprising the polypeptide of the present invention; or antibodies raised against the polypeptide of the present invention, in association with a pharmaceutically acceptable vehicle useful for inducing an immune response in a host.
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified.
Amiloride hydrochloride and hydrochlorothiazide is usually well tolerated and significant clinical adverse effects have been reported infrequently. The risk of hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) with amiloride hydrochloride and hydrochlorothiazide is about 1 to 2 percent in patients without renal impairment or diabetes mellitus (see WARNINGS). Minor adverse reactions to amiloride hydrochloride have been reported relatively frequently (about 20%) but the relationship of many of the reports to amiloride HCl is uncertain and the overall frequency was similar to hydrochlorothiazide treated groups. Nausea/anorexia, abdominal pain, flatulence, and mild skin rash have been reported and probably are related to amiloride. Other adverse experiences that have been reported with amiloride and hydrochlorothiazide are generally those known to be associated with diuresis, thiazide therapy, or with the underlying disease being treated. Clinical trials have not demonstrated that combining amiloride and hydrochlorothiazide increases the risk of adverse reactions over those seen with the individual components.

The adverse reactions for amiloride and hydrochlorothiazide listed in the following table have been arranged into two groups: (1) incidence greater than one percent; and (2) incidence one percent or less. The incidence for group (1) was determined from clinical studies conducted in the United States (607 patients treated with amiloride and hydrochlorothiazide). The adverse effects listed in group (2) include reports from the same clinical studies and voluntary reports since marketing. The probability of a causal relationship exists between amiloride and hydrochlorothiazide and these adverse reactions, some of which have been reported only rarely.

1\. Reactions occurring in 3% to 8% of patients treated with amiloride hydrochloride and hydrochlorothiazide. (Those reactions occurring in less than 3% of the patients are unmarked.)

2. See WARNINGS

3. See PRECAUTIONS

Other adverse reactions that have been reported with the individual components and within each category are listed in order of decreasing severity:
INTRODUCTION AND HYPOTHESIS: Vaginal inserts and continence devices are recommended as a conservative treatment option for the management of stress urinary incontinence (SUI); however, practice patterns for recommendation and use of such devices are currently unknown. Our objectives were to better understand counseling patterns relating to over-the-counter (OTC) continence devices, to assess perceived barriers to recommending these devices, and to estimate clinician familiarity with three such devices currently available in the USA.
METHODS: In this cross-sectional study, an anonymous electronic survey was distributed to all Accreditation Council for Graduate Medical Education-accredited OB/GYN and Urology residency and Female Pelvic Medicine and Reconstructive Surgery (FPMRS) fellowship programs. A total of 326 survey responses were collected. Multivariate logistic regression was used to assess respondent characteristics associated with recommending OTC continence devices to patients.
RESULTS: Sixty-four percent of respondents expressed familiarity with any OTC continence device. Of respondents who reported regular evaluation and treatment of women with SUI (n = 269), 60% reported ever recommending OTC devices for SUI. On multivariate regression, being a trainee and general OB/GYN provider were associated with being less likely to recommend OTC devices for SUI. Of respondents who did not regularly recommend OTC continence devices, reported barriers to doing so included a lack of training with these devices, leading to clinician discomfort (70%) and not remembering OTC devices as an option (15%).
CONCLUSIONS: Given the low risk associated with patient use of these easily accessible devices, our study highlights barriers to clinician recommendation with the goal of increasing clinician awareness and consideration of OTC continence devices.
A medicament compliance monitoring system and method of monitoring medicament compliance are disclosed. The medical compliance monitoring system includes a detector, a transmitter, and a monitoring center. The detector is configured to detect an activity indicative of medical compliance of a medicament. The transmitter is in communication with the detector. The monitoring center is in communication with the transmitter. The transmitter is adapted to communicate data from the detector to the monitoring center in real-time to the occurrence of the activity indicative of compliance. The method includes detecting an activity indicative of medical compliance of a medicament; and transmitting the detected activity to a monitoring center in real-time to the occurrence of the activity indicative of medicament compliance. Also disclosed is a medicament container.
The present invention relates the treatment and prognostic of cancer like glioblastoma. Here, the inventors focused their study on the impact of presence of N6-adenosine methylation in miRNA-200b-3p in samples of patients suffering from glioblastoma multiforme (GBM). Their study was particularly focused on the impact of miRNA-200b-3p and its adenosine methylation on the expression of XIAP. XIAP acts as an anti-apoptotic protein via the inhibition of caspase-3 and -7 activation and high XIAP expression is associated with a poor survival in several solid tumors. Thus, the miR-200b-3p-mediated repression of XIAP mRNA expression appears as a mechanism governing the caspase-3 and -7 activity and the apoptosis. In theory, in the presence of miR-200b-3p, XIAP mRNA expression is repressed and caspase-3 and -7 can be activated to promote apoptosis. Thus, the present invention relates to an in vitro method for determining the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the miR-200b-3p and/or the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) in a sample from said patient and to the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) for use in the treatment of a cancer in a subject in need thereof.
The utility model relates to a chuanketing food sucking tube which belongs to a medicine utensil class. At present, in the prior art, preparation is used for treating cough, such as tablet, powder, aqua, pill, ointment, capsule, granule, medicinal wine, medicinal tea, etc. The curative effects are different, and the medicament has defects of inconvenient carrying and use. In addition, the treatment purpose is very difficult to reach by the drugs because of big smoking addiction and ceaseless cough for patients in smoking crowd, so the utility model uses the food sucking tube made of Chinese herbal medicine ingredients of packaging papers, coltsfoot flowers, mint, lily, honey, etc. When the utility model is used, only by igniting the food sucking tube, the patients suck in smog like smoking, and the smog has inhibiting effect on cough symptoms in a respiratory system, which is favorable to occurrence. Because the therapeutic effect of the utility model is very good, the utility model has the advantage of portability, is suitable for wide crowd and can be widely used in the crowd of the patients suffering from cough.
In primary Endoscopic Retrograde Cholangio-Pancreatography (ERCP) cannulation is wire guided. Up to now there is no doubt about the efficacy of such a procedure. The use of long wire requires the help of another person behind primary operator. The use of short wire rapid exchange allows the primary operator to perform all the steps by himself. Time of cannulation is known to be directly associated to post ERCP pancreatitis.

Aim of the study is to assess which length of guide wire allows the shorter cannulation time during primary ERCP. Post ERCP pancreatitis onset will be assessed for all patients
Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.